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Background: Accurate rapid diagnosis is one of the important steps in the effort to reduce morbidity and mortality
of malaria. Blood-specific malaria rapid diagnostic tests (RDTs) are currently in use but other body fluid specific
diagnostic test kits are being developed. The aim of the present study was to evaluate the performance characteristics
of a one-step Urine Malaria Test™ (UMT) dipstick in detecting Plasmodium falciparum HRP2, a poly-histidine antigen in
urine of febrile patients for malaria diagnosis.
Methods: This was an observational study in which a urine-based malaria test kit was used in malaria diagnosis in
a normal field setting. Two hundred and three individuals who presented with fever (≥37.5°C) at seven outpatient
clinics in Enugu State during periods of high and low transmission seasons in Southeastern Nigeria were enrolled.
Matched samples of urine and blood of consecutively enrolled subjects were tested with UMT and blood smear
microscopy.
Results: With the blood smear microscopy as standard, the disease prevalence was 41.2% and sensitivity for
the UMT was 83.75% (CI: 73.81 to 91.95%, Kappa 0.665, p =0.001). The UMT had an LLD of 120 parasites/μl but
the sensitivity at parasite density less than ≤200 parasites/μl was 50% and 89.71% at density ≥201 parasites/μl
with specificity of 83.48%. The positive and negative predictive values were 77.91% and 88.07%, respectively.
Conclusion: The UMT showed moderate level of sensitivity compared with blood smear microscopy. The test
kit requires further improvement on its sensitivity in order to be deployable for field use in malaria endemic
regions.
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Malaria causes significant morbidity and mortality espe-
cially among children in sub-Saharan Africa. The disease
is caused by the Plasmodium species, which is transmit-
ted to humans by the bite of the female Anopheles mos-
quito. It is estimated that malaria causes about 207
million clinical episodes and about 627,000 deaths* Correspondence: tagbo.oguonu@unn.edu.ng
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unless otherwise stated.annually, mostly in sub-Saharan Africa [1]. One of the fac-
tors that have ensured the persistence of malaria and the
morbidity/mortality has been the failure of early diagnosis
and prompt treatment of the disease [2,3]. Until recently,
presumptive diagnosis based on clinical algorithm in highly
endemic areas has been the most used method [4,5], but is
been found unreliable and contributed to over-diagnosis of
malaria, leading to wastage of anti-malarial drugs [6].
However, in recent times, with relatively high cost and
increasing incidence of resistance to anti-malarial drugs,
it has become necessary to confirm cases of malaria
using laboratory methods before treatment. Thick smear
microscopy based on the demonstration of the presencel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ard for the diagnosis of malaria [4].
However, this method is highly operator-dependent
and requires initial and ongoing training to maintain
high quality testing; such quality assurance practices
have often been difficult to implement in resource poor
and malaria endemic countries. In addition, there has
been reported over-diagnosis of malaria using micros-
copy in health facilities [6,7], with its consequent effect
on drug resistance and toxicity. To reduce these defi-
ciencies, the malaria rapid diagnostic test (malaria RDT)
kits have been developed and deployed in many coun-
tries for the rapid diagnosis of clinical malaria.
These kits use immune-chromatographic materials im-
pregnated with monoclonal antibodies against Plasmodium
species to detect the parasite antigen in blood of infected
patients. Most of these kits use antigens or enzymes de-
rived from parasites that have infected humans. The com-
monly used one is the histidine rich protein 2 (HRP2),
which is produced by Plasmodium during its asexual forms
and early gametocytic stages in infected individuals. It is a
water soluble substance abundantly found in the para-
site cytoplasm and serum of infected individuals. Histi-
dine rich protein 2 is secreted early during infection by
the Plasmodium parasite and persists after treatment.
Significant levels of HRP2 antibodies in some infected
individuals reduce the sensitivity of the protein dependent
test kits [4]. Sensitivities of the HRP2 kits are affected by
factors which are dependent on the protein, the individual
and manufacturing. Environmental factors such as high
temperatures are equally known to affect sensitivities [4].
Over time, the HRP2 based rapid diagnostic test kits have
improved on their sensitivity and specificity to the ranges
of 80% to 95% compared with malaria microscopy [8]. In
order to standardize the efficacy of the malaria RDT kits,
the WHO set the lowest level of detection (LLD) accept-
able in areas of high malaria endemicity for all malaria
RDTs to be 100 parasites/μl [9], However, due to poor cor-
relation noted between the low parasite density (<100 par-
asites/μl) and RDTs, another point of 200 parasites/μl was
set as standard for diagnostic test kits for field tests [10].
HRP2 have been found in several body fluids such as
urine, saliva, blood [11]. These findings increased interest
in the use of malaria RDTs for diagnosis of malaria in
these types of body fluids. With concerns about blood-
borne pathogen exposures, cultural taboos and procedural
difficulties, the advantages of the use of urine as test
matrix include low risk and relative ease of access of the
sample. Blood-based malaria RDTs have been evaluated
for malaria detection in urine with unsatisfactory results
[12,13]. The performance may be attributed to the degrad-
ation or proteolytic cleavage of urine-excreted proteins
[14,15], which may necessitate the use of appropriately
specific kits that can identify specific malaria antigens inthe urine. Recently, a urine based malaria test kit (UMT)
has been developed by Fyodor Biotechnologies Baltimore,
USA for the diagnosis of malaria. The UMT is a re-
combinant monoclonal antibody based test that detects
Plasmodium falciparum specific HRP2, a poly-histidine
protein, or fragment present in the urine of febrile
patients.
The present study was performed to assess the diag-
nostic accuracy of the UMTin malaria diagnosis in com-
parison with benchmarked gold standard, blood smear
microscopy.
Methods
This was an observational cross-sectional diagnostic test
study in which participants with fever at presentation
were enrolled consecutively at different health facilities
in both urban and rural communities of Enugu State. Insti-
tutional ethical approval was obtained from the University
of Nigeria Teaching Hospital Health Research Ethics
Committee prior to the start of the study. Individuals
who met inclusion criteria were properly consented
before enrollment.
Study site
Enugu State has a population of 3.6 million inhabitants
and located in the rain forest region of southeast Nigeria.
The region is endemic for malaria and with year-round
transmission of the disease. The highest transmission is in
the rainy season from the month of April to October.
The inclusion criteria were: fever of ≥37.5°C and non-
use of anti-malarial drugs in the preceding one week.
Adults and children with history of haematuria were ex-
cluded from the study (haematuria is a feature of many
diseases with probable high level of antibody that may
cause false positive results.). Demographic information
such as age, gender, symptoms of disease as well as
physical examinations were also obtained from each par-
ticipant. Subsequently the matched capillary blood
drawn from finger/heel pricks and urine samples voided
into a universal bottle were respectively stained in accord-
ance with WHO standard microscopy technique [16] and
immediately tested with the UMT kit (Lot No. K06K-0,
Fyodor Biotechnologies, Baltimore, Maryland, USA).
Principles and procedure for Urine Malaria Test™ (UMT)
The technology relies on the fact that clinical malaria
commonly results in elevated levels of specific proteins
(Histidine Rich Protein-2) or its protein fragments in pa-
tient’s urine against which cognate recombinant monoclo-
nal antibody reagents were developed. It is a qualitative
assay consisting of a nitrocellulose membrane strip con-
taining relevant antibody reagent and controls that are
each immobilized at the specific individual site on the
membrane. When the immunochromatographic dipstick
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in the urine migrate and interacts with immobilized cog-
nate monoclonal antibody resulting in dark-colored strips
on the dipstick. The UMT strips were individually pack-
aged in a sealed Mylar foil pouch with a desiccant, and
stored at room temperature for the entire period of the
study.
Sample testing
To perform the urine test, the UMT strip was dipped in
200 μl of urine for two minutes to allow the sample to
wick and saturate the strip. The strip was then removed,
placed on its foil pouch packaging and incubated for
20 minutes. The results were reported as negative, posi-
tive, or un-interpretable: if two visible lines appeared on
the strip (even if very faint) the test was positive; if only
the control line appeared, the test was negative. Tests re-
sults reported as un-interpretable, i.e., failure to observe
a control line or the presence of a darkly stained back-
ground that obscured the test lines, were repeated to re-
solve the discrepant event.
Blood microscopy
The capillary blood samples drawn from finger/heel
pricks of the subjects were used to perform thick smear
microscopy. Preparation of these blood samples (three
thick blood smear slides per participant) for microscopy
were in accordance with WHO standard microscopy
technique [16], and read with × 1,000 magnification (with
oil immersion lens). Two trained and experienced micros-
copists at the laboratory read the slides independently.
Microscopy was considered positive only when asexual
parasite forms – trophozoites and schizonts (not ga-
metocytes alone) – were detected, since asexual forms
are indicative of active infection. Parasite densities were
determined by counting the number of parasites seen per
200 white blood cells, and the parasite density per micro-
litre was calculated based on the putative mean count of
8,000 leucocytes per microlitre using the formula [4,16]:
Parasitaemia per microlitreð Þ ¼ number of parasites  8; 000
200 leucocytes
However, if 500+ parasites have been counted without
having reached 200 leucocytes, the count was stopped
after completing the reading of the last field, and the
parasitemia was calculated using the above formula. Also
100 fields of the second thick film were examined to
identify mixed infections, which were confirmed on the
thin film in case of any doubt. A blood film was assumed
negative when the examination of 100 thick film fields
did not show the presence of asexual forms of P. falciparum.
The same technique was employed for establishing the
parasite density on each of the subsequent blood film
examinations.To yield a final microscopic interpretation, the two
study microscopists independently agreed on three cri-
teria: (i) on the presence or absence of asexual stages of
Plasmodium; (ii) on the species of Plasmodium, when
one was present; and (iii) on the calculated level of para-
sitaemia within a 10% error margin [17,18].
Data management and analysis
All clinical and laboratory data were entered into the cor-
responding logbooks and transcribed into Excel worksheet
(Windows 7, Microsoft Inc., Richmond, Washington
2011) and analysed with Statistical Package for Social
Science (SPSS) version 20. (IBM Inc. Chicago, Illinois).
Descriptive statistics were used to ascertain the fre-
quency distribution, mean, median and standard devi-
ation of the subject characteristics; age, temperature,
clinical symptoms. The outcome variables: the parasite
densities and the UMT results were expressed in pro-
portions (percentages), categorized for determination
of sensitivity, specificity and predictive values (positive
and negative). Chi square tests were used to test for
the significance of the UMT results and other subjects’




From a total of 638 individuals who were screened, 203
who met the inclusion criteria were enrolled from all the
health facilities between June and December 2012, span-
ning periods of high and low malaria transmission in the
study area. Data from 203 subjects were analysed; three
children who could not void urine and five that had in-
complete information were excluded giving final number
of 195 subjects. Sixty four percent of the participants
were females and 90.3% were children (aged less than
18 years old). The median age was three years with the
range of six months to 60 years (Table 1). All the partici-
pants presented with fever (≥37.5°C) at enrollment, with a
median body temperature of 38.1°C, (mid quartile range:
37.7°C to 38.9°C).
Malaria microscopy
Eighty (41.03%) out of the 195 participants had positive
malaria P. falciparum parasites with microscopy Table 2.
The parasite infection rates with blood smear micros-
copy among children and adults screened were 37.43%
and 3.58%, respectively. The parasite density geometric
mean was 62,778.9 parasites/μl with a range of 60 to
792,600 parasites/μl and grouped median of 9080 para-
sites/μl. The microscopy specie identification showed
P. falciparum in blood specimen of all the subjects out
of which 64.1% had a mixed infections of P. falciparum
and Plasmodium vivax.
Table 3 Sensitivity of UMT with microscopy at different
parasite densities
Parasite densities (parasites/μl)
Parameters ≤ 100 ≤ 200 ≥ 201 Overall
Sensitivity 0 50% 89.71% 83.75%








PPV 0% 24% 76.25% 77.91%








NPV 97.96% 94.12% 93.20% 88.07%








Table 1 The demographic characteristics and parasite
densities of the study population
General characteristics
Age (SD) years 6.80 (11.45)
Median (quartile range) years 3 (3 to 5.91)
Age groups (%)
< 5 years 144 (73.8%)
5-18 years 31 (15.9%)
>18 years 20 (10.3%)
Species Identification (%)
Plasmodium falciparum (Pf ) 66 (30.4%)
Pf and P vivax 125 (64.1%)
Geometric mean parasite density 62, 778.85
parasites/μl
Grouped Median (range) 9,080 (60 to 792, 600
parasites/μl
SD = Standard deviation.
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Eight-six (44.1%) of 195 were positive with the UMT
test. Parasite rates were 41.03% and 3.0% among chil-
dren (<18 years) and adults, respectively. Overall, the
UMT in comparison with the malaria microscopy showed
sensitivity of 83.75% (95% CI: 73.81 to 91.95%, Kappa
0.665, p =0.001) and specificity of 83.48% (95% CI: 75.41%
to 89.75%), Table 3. The device showed different sensitiv-
ities for different malaria parasite densities (PD) as follows:
PD ≤100 parasites/μl: 0%, PD ≤200 parasites/μl: 50%,
PD ≥201 parasites/μl: 89.71%, respectively Table 3. The
lowest parasite density detected was 120 parasites/μl.
Two of the urine samples showed a negative UMT re-
sult in the presence of high malaria parasite densities
(61,520 and 100,269 parasites/μl) with microscopy. There
were 19 false positive results of which one was due to the
presence of gametocyte alone in the blood smear. Indeter-
minate results were observed in one test which on repeat
showed a faint positive result. Most commonly observed
was the degradation of the test results over time (within
one hour post-test).
Among the different age groups, false positive results
were less frequent among the adults than the children
(8.3% versus 17.14%, p = 0.001), while the false negative




UMT Positive 67 19 86
Negative 13 96 109
Total 80 115 195versus 28.57%, p = 0.001). Overall, the positive predictive
(PPV) and the negative predictive values (NPV) for the
UMT were 77.91% and 88.07%, respectively.Discussion
The UMT prototype has shown a higher level of sensitivity
than previously tested blood specific RDT kits in urine
specimens [12,13]. Genton et al. using ParaSight®-F to test
urine samples of malaria patients obtained sensitivity and
specificity of 81% and 26%, respectively [13]. Other studies
as well with non-blood samples showed comparatively
poorer sensitivity results: saliva (73%) and urine (32%) [13].
The UMT had an LLD of 120 parasites/μl, and a 50%
sensitivity at ≤200 parasites/μl which is the revised accept-
able standard for field tests [10,19] it however requires
further improvement despite the corresponding good spe-
cificity. There could be many reasons for the relative poor
sensitivity at lower parasitaemia levels, which may be
related to parasite antigen production, antigen content in
urine and time of void [20,21]. Genton et al. [12] noted
that the amount of malaria antigen was low in urine and
dependent probably on the time of collection of the sam-
ples [12]. They suggested that first void morning urine
might probably give better sensitivity than later timed
samples. This may not be practicable in clinical practice
where the results are required for immediate treatment.
With the probable variability in malaria antigen quantity, it
is likely that the expected amount of antibody impregnated
in the urine-specific test kits as well as the quantity of body
fluid required may be higher than those of blood-specific
test kits thus necessitating a probable further optimization
of the Fyodor UMT to enhance test sensitivity in low
parasitaemia. It is known that the property of the antibody
impregnated in the nitrocellulose pad of the immunochro-
matographic test kits also determine the sensitivity. For
instance the monoclonal or polyclonal antibodies affect the
degree different of the malaria RDTs [20]. At higher
parasite densities (≥200 parasites/μl of blood) the UMT
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the results of blood based test kits [4,21] in blood samples.
The degree of false positive results especially among
children may suggest that the UMT is able to maintain
acceptable level of false positive results particularly in
areas of high malaria transmission [22,23]. Also the
false positivity related to the presence of the gameto-
cyte is indicative of the ability to detect sexual form of
P. falciparum a factor which is useful in absolute sensi-
tivity tests against the clinical episodes that was used in
this study. However, in areas of low malaria endemicity,
this level of false positives may create drug wastage, which
the current malaria control efforts seek to reduce. False
positive results may be attributed to the ability of all
histidine-rich protein 2 (HRP2) antigen malaria test kits to
detect the parasite antigen even after malaria illness. The
presence of rheumatoid factor and schistosomiasis in a pa-
tient may also lead to false positivity, and will need to be
further evaluated [24-26]. These factors are known to
affect the blood type malaria RDTs, but little is known
about such influence on the urine malaria test kits. It may
be assumed that since both (blood and urine-based) test
kits are specific for HRP2 such effect may also occur with
the UMT.
The UMT specificity remained constant at significant
levels for the different parasite densities although this
may cause significant morbidity and mortality in areas of
high endemicity. The false negative results with UMT
are comparable to those of blood-specific malaria RDTs
[4,11,12,21]. Many factors have been described to con-
tribute to the false negative results with HRP2-based
rapid test kits. These include parasite and host factors
such as deletion or mutation of HPR2 gene [27], the
presence of antibodies to HRP2 in the presence of high
malaria density [4,27]. The two cases noted in this index
study that had high malaria parasite count greater but
with negative UMT results may be an illustration of the
prozone effect observed with immunochromatographic
tests such as malaria RDT [28-30].
Some of the limitations observed with the use of the
urine malaria test kit were the high color degradation of
the test line within an hour after testing. This is a disad-
vantage, which makes it difficult to crosscheck the re-
sults in cases of doubt. The delay in provision of some
subjects, particularly among children, may be a delay
factor in the promptness of testing and treatment. The
sample size may also may be a factor in the resultant ac-
curacy result, which may probably be answered by the
completed larger clinical trials.
Conclusion
The Urine Malaria Test kit studied has shown moderate
concordance with blood smear microscopy and higher
levels of sensitivity than blood-based test kits used formalaria diagnosis with urine. The UMT used for the
study is still undergoing further development and evalu-
ation, with opportunity for further improvement particu-
larly in the area of test stability and sensitivity at lower
parasite levels before the kit can be fully deployed for
general use. Optimization of the detected areas of defi-
ciency will enhance the usefulness of the non-blood
based kits such as the UMT as a reliable and easy to use
alternative tool in the diagnosis of malaria in the areas
where the competence for blood microscopy is not reli-
able, and safety concerns are expressed.
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